

²
~~3~~ ¹¹ (New) The method of claim ~~10~~ wherein the locally effective TNF- α lowering amount of bioactive glass particles is administered prophylactically or therapeutically to prevent or treat peritoneal adhesions.

cont
B2
⁴
~~4~~ ¹⁸ (New) The method of claim ~~10~~ wherein the locally effective TNF- α lowering amount of bioactive glass particles is administered by intraperitoneal injection of a composition comprising the bioactive glass particles, a suitable carrier for intraperitoneal injection, and one or more therapeutic agents.

⁵
~~5~~ ¹⁹ (New) The method of claim ~~18~~ wherein the one or more therapeutic agents are selected from the group consisting of healing promotion agents, growth factors, anti-inflammatory agents, and anesthetics.

⁶
~~6~~ ²⁰ (New) The method of claim ~~16~~ wherein the bioactive glass particles have a size less than about 2 microns.

⁷
~~7~~ ²¹ (New) The method of claim ~~12~~ wherein the locally effective TNF- α lowering amount of bioactive glass particles is administered by inhalation.

⁸
~~8~~ ²² (New) The method of claim ~~12~~ wherein the locally effective TNF- α lowering amount of bioactive glass particles is administered by subcutaneous injection.

⁹
~~9~~ ²³ (New) The method of claim ~~22~~ wherein the locally effective TNF- α lowering amount of bioactive glass particles is mixed with a biocompatible hydrogel.

¹⁰
~~10~~ ²⁴ (New) The method of claim ~~22~~ wherein the locally effective TNF- α lowering amount of bioactive glass particles is administered at a site at which surgery is to be performed.

¹¹
~~11~~ ²⁵ (New) The method of claim ~~24~~ wherein the locally effective TNF- α lowering amount of bioactive glass particles is mixed with an anesthetic.
